 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share...

Neuropsychiatric-Focused Vanda Pharmaceuticals Rejects Future Pak's Takeover Bid Valued Up To $7.75/Share

Vanda Pharmaceuticals rebuffs unsolicited proposals from Future Pak LLC, citing undervaluation. Offers up to $7.75 per share. Board asserts resilient business with FDA-approved products. Future Pak...

Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan PR Newswire WASHINGTON, April 17, 2024 WASHINGTON, April...

Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak PR Newswire...

Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak

StockNews.com downgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA - Free Report) from a buy rating to a hold rating in a research report released on Saturday morning.
Separately, TheStreet...

Vanda Pharmaceuticals (NASDAQ:VNDA) Downgraded by StockNews.com to "Hold"

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much...

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

Vanda Pharmaceuticals' Fanapt (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder Vanda Pharmaceuticals' Fanapt (iloperidone) Receives U.S. FDA Approval for the...

Vanda Pharmaceuticals' Fanapt (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) was upgraded by StockNews.com from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Friday.
Separately...

Vanda Pharmaceuticals (NASDAQ:VNDA) Rating Increased to Buy at StockNews.com

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceutical Inc. ( Vanda or the Company ) (NASDAQ: VNDA). Such investors are...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA

Syndax Pharmaceuticals SNDX stock rose 7.6% on Mar 27 after it announced a day before that the FDA had granted a priority review to its new drug application (NDA) for pipeline candidate revumenib...

Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Volume (M)	2.44M
52-Wk High	$7.00
52-Wk Low	$3.30

VNDA Vanda Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals